There is an ongoing phase III trial assessing RC48 efficacy in advanced GC (2.5 mg/kg Q2W) versus physician’s choice (NCT04714190) as well as numerous other trials in HER2-expressing cancers (NCT05996952, NCT05955209, NCT05980481, NCT0513715, NCT04329429). This evidence concerns the gene ERBB2 and gastric cancer.